Home / Remifentanil / United States
US ATC N01AH06 · updated 2 Nov 2026
Remifentanil shortage in United States
Is there a Remifentanil shortage in United States?
Yes. As of 2 Nov 2026, 9 Remifentanil products are reported short in United States, the first since 28 Jun 2022. No return date has been given. Main reason: not stated.
Also short in Canada, Czechia, Norway, Australia. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10) | Hikma Pharmaceuticals USA, Inc. | 28 Jun 2022 | not given | Increased demand Demand increase for the drug |
| US | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03) | Fresenius Kabi USA, LLC | 28 Jun 2022 | not given | Distribution or logistics Delay in shipping of the drug |
| US | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05) | Fresenius Kabi USA, LLC | 28 Jun 2022 | not given | Not stated |
| US | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10) | Fresenius Kabi USA, LLC | 28 Jun 2022 | not given | Not stated |
| US | Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10) | Hikma Pharmaceuticals USA, Inc. | 28 Jun 2022 | not given | Increased demand Demand increase for the drug |
| US | Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10) | Hikma Pharmaceuticals USA, Inc. | 28 Jun 2022 | not given | Increased demand Demand increase for the drug |
| US | Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01) | Mylan Institutional, a Viatris Company | 28 Jun 2022 | not given | Not stated |
| US | Ultiva, Injection, 2 mg (NDC 72078-035-02) | Mylan Institutional, a Viatris Company | 28 Jun 2022 | not given | Not stated |
| US | Ultiva, Injection, 5 mg (NDC 72078-036-05) | Mylan Institutional, a Viatris Company | 28 Jun 2022 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).